AstraZeneca is a medical device company that manufactures Xigduo XR — a controversial device that has recently been linked to Kidney disease and ketoacidosis.

Xigduo XR contains two prescription medicines called dapagliflozin and metformin. The SGLT2 inhibitor is also used along with diet and exercise to improve blood sugar control in adults with Type 2 diabetes when treatment with either dapagliflozin or metformin has not controlled it properly.

Lawsuits allege that manufacturers and marketers of SGLT2 inhibitors failed to warn patients and physicians of the increased risk of kidney failure, heart attacks, and ketoacidosis. The FDA warned that users of the drug were at risk for diabetic ketoacidosis. This is rare, but it could be a fatal side effect. The agency had received at least 20 reports of diabetic ketoacidosis between March 2013 and June 2014.

Why is Xigduo XR Dangerous?

Xigduo XR is an SGLT2 inhibitor that has caused many users to suffer because of ketoacidosis and acute kidney injury. This is typically a problem that occurs when the blood becomes too acidic; ketones build up when sugar cannot be used by cells for energy and the body must use fat storing instead.

This side effect can be fatal, and others have experienced life-long health problems from this and other Type 2 diabetes drugs, including Farxiga, Free Case Review Box on this page, or

  • Call (866) 280-3417 any time of day to tell us about your case.
  • We will listen to your story and answer your questions. If you have a claim, we will start immediately.

    WARNING: There are strict time deadlines for filing Xigduo XR lawsuit claims.

     

    • Was this information helpful?
    • Yes   No